Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors.

CONCLUSIONS: MEDI1873 showed acceptable safety up to 500 mg IV Q2W with pharmacodynamic activity, and prolonged SD in some patients. However, further development is not planned due to lack of demonstrated tumor response.
PMID: 32887725 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - September 3, 2020 Category: Cancer & Oncology Authors: Balmanoukian A, Infante JR, Aljumaily R, Naing A, Chintakuntlawar AV, Rizvi NA, Ross HJ, Gordon M, Mallinder PR, Elgeioushi N, González-García I, Standifer N, Cann J, Durham N, Rahimian S, Kumar R, Denlinger CS Tags: Clin Cancer Res Source Type: research